ライフサイエンスコーパス: severe pain

1 0 to 10, with higher scores indicating more severe pain).

2 nt, ventilation use, benzodiazepine use, and severe pain).

3 to -0.029) on a scale from 0 (no pain) to 3 (severe pain).

4 rious adverse events (primarily bleeding and severe pain).

5 : 1.01-14.9) were associated with persistent severe pain.

6 arter were aggressive, mainly verbally, with severe pain.

7 Sickle cell disease causes severe pain.

8 rized in most kindreds by early-age onset of severe pain.

9 More than 60% of Latinos reported severe pain.

10 potent analgesic drugs for the treatment of severe pain.

11 A score of >or=7 was defined as severe pain.

12 erized by loss of feeling in extremities and severe pain.

13 d after onset of a migraine with moderate to severe pain.

14 the choice for the treatment of moderate to severe pain.

15 ugs (NSAIDs) in the treatment of moderate to severe pain.

16 resent a new therapeutic approach to control severe pain.

17 e patients reported experiencing moderate to severe pain.

18 terminally ill patients reported moderate or severe pain.

19 ts had no body pain; 38% had moderate and 4% severe pain.

20 re were 2554 visits; 60% of the patients had severe pain.

21 algesics are widely used in the treatment of severe pain.

22 t supplies of opioids to treat patients with severe pain.

23 algesics; 41% of patients reporting pain had severe pain.

24 mplained of shortness of breath, chills, and severe pain.

25 but without injection, hypopyon, fibrin, or severe pain.

26 on hyperexcitability, which in turn produces severe pain.

27 ilities, particularly poor mental health and severe pain.

28 pillars, produce defensive venoms that cause severe pain.

29 prescribed for the treatment of moderate or severe pain.

30 ts undergoing spine surgery often experience severe pain.

31 been widely applied for treating moderate to severe pain.

32 cating moderate pain, and 7 to 10 indicating severe pain.

33 ecisions for pregnant women with moderate to severe pain.

34 e seen in 6 patients; 8 patients experienced severe pain.

35 s is an attractive alternative treatment for severe pain.

36 , causes debilitating joint inflammation and severe pain.

37 Opioids are the gold-standard treatment for severe pain.

38 natives for the pharmacological treatment of severe pain.

39 10-point scale, with 10 indicating the most severe pain.

40 t and most potent drugs for the treatment of severe pain.

41 mainstay analgesics for treating moderate to severe pain.

42 trical shocks can damage the heart and cause severe pain.

43 tients with Parkinson's disease and chronic, severe pain.

44 pain, 10.3% had moderate pain, and 13.2% had severe pain.

45 ids for moderate pain and strong opioids for severe pain.

46 n clinical trials for the treatment of acute severe pain.

47 analgesics for the treatment of moderate to severe pain.

48 reported intermediate pain, and 12% reported severe pain.

49 se with moderate pain, and 67% of those with severe pain.

50 and presented with similar symptoms, such as severe pain.

51 associated with receiving OPs for those with severe pain.

52 mong the most used clinical drugs to relieve severe pain.

53 verbal rating scale, from "no pain" to "very severe pain."

54 More specifically, for those with severe pain, 41% filled an OP within 7 days of assessmen

55 .4%, P < .001), self-reported pain (moderate/severe pain, 41.1% vs 24.2%, P = .003), burning/stinging

56 ry vision (93%), floaters (60%), pain (44%), severe pain (6%), and photophobia (19%).

57 Among those with chronic severe pain, 65% of MMTP patients and 48% of inpatients

58 %) observations of patient-reported moderate/severe pain, 748 of 2039 observations (36.7%) of patient

59 6) and reported similar rates of moderate to severe pain (85% vs 91%; relative risk [RR], 0.77 [95% C

60 ced cancer who were experiencing moderate-to-severe pain; 90% were enrolled in hospice.

61 axis patient experience was characterized by severe pain, a lack of adequate pain management, limited

62 ar old male child presented to casualty with severe pain abdomen since 1 day.

63 ufficient medications to treat patients with severe pain adequately.

64 gery, controlling for pre-operative moderate-severe pain: Adjusted odds ratio = 0.25 (95% CI: 0.07 -

65 t different pain profiles (affected son with severe pain, affected mother with moderate pain, and an

66 a well-recognized problem, with moderate to severe pain affecting 15% to 20% of women at 1 year from

67 Most women report moderate to severe pain after cesarean delivery.

68 ificant portion of patients still experience severe pain after major surgery.

69 who have an operation experience moderate to severe pain after surgery.

70 roblem in lactating women that may result in severe pain and abrupt termination of breastfeeding, the

71 oid drugs are potent analgesics for treating severe pain and are commonly used during general anesthe

72 are an economic burden worldwide; they cause severe pain and bleeding, and are the leading cause of h

73 substantial morbidity caused by moderate to severe pain and by spinal cord compression.

74 tients with advanced cancer with moderate to severe pain and clinician-estimated life expectancy of 6

75 End-stage ankle osteoarthritis causes severe pain and disability.

76 Persistent severe pain and faecal urgency has been found in a distu

77 ndergoing investigation for the treatment of severe pain and HIV, respectively.

78 of patients suffer from MBD associated with severe pain and increased mortality.

79 icial sources as tanning lamps can result in severe pain and inflammation in the cornea.

80 als such as ammonia (smelling salts) elicits severe pain and inflammation through unknown mechanisms.

81 ading to spinal imbalance that can result in severe pain and neurological deficits, thus significantl

82 Severe pain and osteoarthritis predict regular use of CA

83 to bone to form osteolytic lesions, causing severe pain and pathological fracture.

84 ave reported a high incidence of moderate to severe pain and poor analgesia in intensive care units a

85 vs unexposed pseudopopulations) observed for severe pain and poor mental health.

86 n the relationship between moderate and more severe pain and prescription opioid use disorders in the

87 altrexone for patients endorsing moderate to severe pain and randomized early while still undergoing

88 Neuroimmune interactions may contribute to severe pain and regional inflammatory and autonomic sign

89 The features of this disorder include severe pain and sensory, autonomic, motor, and trophic a

90 is a common vasospastic disorder that causes severe pain and ulcers, but despite its high reported he

91 Patients with unstable SCFE are in severe pain and unable to bear weight.

92 s a life-altering condition characterized by severe pain and uncertainty on multiple fronts.

93 performed among adults with moderate or more severe pain and with nonmedical opioid use at wave 1.

94 cell anemia age 5-17 years hospitalized with severe pain and/or ACS.

95 with 0 indicating no pain and 10 indicating severe pain) and opioid consumption (measured in morphin

96 is characterized by a more acute onset, more severe pain, and a rapid response to systemic corticoste

97 IV Parkinson's disease, at least one type of severe pain, and an average 24-h pain score of at least

98 ated for groups with and without moderate to severe pain, and these risk differences were tested for

99 ng to periapical inflammation, bone erosion, severe pain, and tooth loss.

100 alternatives for treatment of high fever and severe pain are limited.

101 least 88% of cancer deaths with moderate to severe pain are untreated.

102 dvanced stage cancers frequently suffer from severe pain as a result of bone metastasis and bone dest

103 ith a mean of 9 and 28 (71%) described their severe pain as excruciating.

104 es that were sufficient to treat patients in severe pain, as compared with 72 percent of pharmacies i

105 rapid initiation of opioids for treatment of severe pain associated with a vasoocclusive crisis, and

106 action potential firing, consistent with the severe pain associated with envenomation.

107 sics are traditionally the treatment for the severe pain associated with this disease.

108 They are useful in acute instances involving severe pain associated with trauma, surgery, and termina

109 Children who had more severe pain at baseline in both groups (P = .0065) had w

110 For patients with moderate-to-severe pain at baseline, the rate of response was signif

111 he proportion of women reporting moderate or severe pain at follow-up was 32% (10 of 31) among those

112 In ITT, moderate or severe pain at follow-up was reported by 58 of 115 women

113 ients with prodromal symptoms or moderate or severe pain at presentation were also more likely to exp

114 Severe pain at sites of known tumor was dose limiting at

115 0 to 10, with higher scores indicating more severe pain) at 6 months after enrollment.

116 al rating scale (score 0-5; 0 = no pain, 5 = severe pain) before surgery and 6 weeks postoperatively.

117 nonsurgical palliation reported moderate to severe pain beyond the third month of treatment.

118 Among those with severe pain, black patients were less likely to receive

119 eptor (MOR) agonists are often used to treat severe pain but can result in adverse side effects.

120 inctive rare condition characterized by less severe pain but marked autonomic activation during attac

121 Opioids remain the mainstay of treatment for severe pain, but the associated hyperalgesia and toleran

122 jury of peripheral nerves may quickly induce severe pain, but the mechanism remains obscure.

123 Opioids are commonly used as analgesics for severe pain, but their addictive potential has sparked a

124 and dependence among adults with moderate to severe pain, careful monitoring and consideration of non

125 pioids are essential analgesics for managing severe pain caused by cancer, surgery, and tissue injury

126 st widely prescribed therapy for moderate to severe pain clinically, they have been noted to alter mi

127 wer in painful-DPN individuals with moderate/severe pain compared with those with low pain.

128 MOR agonist prescribed for the treatment of severe pain conditions that has addictive properties.

129 Severe pain creates fatigue, impairs concentration, comp

130 a highly variable phenotype characterized by severe pain crises, acute clinical events, and early mor

131 Prevalence of chronic severe pain, defined as pain that persisted for more tha

132 The clinical management of severe pain depends heavily on opioids acting through mu

133 The prevalence of moderate or severe pain did not change among all decedents or in any

134 ssociated with fewer days of severe and very severe pain (difference of -0.22 days; 95% CI, -0.41 to

135 ded voltage-gated Na(+) channel NaV1.9 cause severe pain disorders ranging from neuropathic pain to c

136 ing stable opioid therapy and experiencing a severe pain episode were randomly assigned to either 100

137 apy to become the standard for management of severe pain events in children and adults with SCD requi

138 elf-limited toxicities of 3F8 treatment were severe pain, fever, urticaria, and reversible decreases

139 ading to inflammation, bone destruction, and severe pain for the patient.

140 in (for non-opioid analgesics) and strong to severe pain (for opioid analgesics).

141 bone and induce bone destruction leading to severe pain, fractures, and other skeletal-related event

142 and intervention for a middle-aged man with severe pain from spinal metastases to discuss 4 key ques

143 rol was more likely among patients with more severe pain, greater anxiety, depression, and alteration

144 The reduction in severe pain (> 5 on a scale of 1 to 10) from 27.0% to 19

145 trial, patients with one CAF and moderate-to-severe pain (>/=50 mm on a 100 mm visual analog scale [V

146 opioids for alleviation of persistent and/or severe pain; however, multiple preclinical and clinical

147 ntanyl, are widely used for the treatment of severe pain; however, prolonged treatment with these dru

148 Few participants complained of moderate to severe pain in any group immediately after the procedure

149 extremities and axial pain with moderate or severe pain in at least one of the three regions.

150 f a tertiary care centre with a complaint of severe pain in both hip joints.

151 orphine the opioid of choice for moderate to severe pain in cancer?

152 eutic agents of choice to manage moderate to severe pain in patients with advanced cancer, however th

153 Vaso-occlusive pain episodes (VOE) cause severe pain in patients with sickle cell disease (SCD).

154 However, these drugs can cause severe pain in patients, commonly referred to as calcine

155 However, these drugs can cause unexplained severe pain in patients, often referred to as calcineuri

156 Current treatment of moderate to severe pain in SCD is mostly reliant upon opioids; howev

157 tance): pain in the back or lower extremity, severe pain in the operated hip, poor mental health, mor

158 ed in diabetic patients with sudden onset of severe pain in the thigh or calf muscles who have MR ima

159 se hyperexcitability of Na(V)1.7 and lead to severe pain in this debilitating disease.

160 closely matches the incidence of moderate to severe pain in trauma patients, indicating appropriate p

161 eat tail-flick test, an assay of moderate to severe pain in which opioids are effective.

162 ts millions of women and is characterized by severe pain, increased frequency of micturition, and chr

163 urden of pain (mild to moderate or strong to severe pain index) was observed at regional and remote s

164 Among those with chronic severe pain, inpatients were significantly more likely t

165 cation, had a migraine attack of moderate or severe pain intensity at baseline, and provided at least

166 ication for a migraine attack of moderate or severe pain intensity, and provided at least one efficac

167 = 563) for a migraine attack of moderate or severe pain intensity.

168 reat a single migraine attack of moderate or severe pain intensity.

169 reat a single migraine attack of moderate or severe pain intensity.

170 ated a single migraine attack of moderate or severe pain intensity.

171 pharmacologic treatments is increasing, more severe pain interference may inhibit this access.

172 PEG responses indicated severe pain interference with activities of daily living

173 Although severe pain is a major clinical manifestation of SCD, it

174 Severe pain is a widespread health problem in need of no

175 ht be a useful pain-regulation strategy when severe pain is expected.

176 Chronic severe pain is prevalent among patients in substance abu

177 One patient had severe pain lasting 2 weeks, followed by milder pain for

178 Limited options for treating moderate-severe pain led to an overreliance on opioids and the cu

179 ndards were developed for minor pain (<30%), severe pain (<3%), vasovagal hypotension (<3%), signific

180 Opioids remain the mainstay of severe pain management in patients with cancer.

181 d pain (median 14 months, 13-NA) or moderate-severe pain (median 11 months, 9-13).

182 Four in 10 patients had severe pain most of the time.

183 strong opioids in survivors with moderate to severe pain, most pain problems in cancer survivors will

184 all Ultraflex; n=6), food obstruction (n=3), severe pain (n=2), esophageal rupture (n=2), hemorrhage

185 Severe pain/narcotic dependency, tumor size larger than

186 ioid was administered on 57.0% (n = 14,975), severe pain occurred on 7.0% (n = 1,829), and delirium o

187 reported extremely severe pain or moderately severe pain occurring at least half of the time, and nea

188 tis (odds ratio, 5.6 [95% CI, 1.9 to 16.8]), severe pain (odds ratio, 2.5 [CI, 1.4 to 4.8]), and a co

189 intestinal tract or abdominal viscera causes severe pain often with vomiting due to oedematous bowel

190 Severe pain on awakening (POA) and emergence delirium (E

191 n 1014 patients, 55% experienced moderate-to-severe pain on the first postoperative day.

192 gnificant effect of PePS on odds of moderate-severe pain (on average over the last week) at 3-months

193 minally ill patients experienced moderate to severe pain, only 30% of them wanted additional pain tre

194 Patients might have severe pain or be asymptomatic.

195 Nearly 15% reported extremely severe pain or moderately severe pain occurring at least

196 Moderate to severe pain or stiffness was reported in 55% of patients

197 stablished on ART, and reporting moderate-to-severe pain or symptoms.

198 We identified five women who reported severe pain or vaginal wounds, six reports of allergies

199 oderate pain (OR 0.55, 95% CI 0.40-0.76), or severe pain (OR 0.22, 95% CI 0.16-0.31).

200 oderate pain (OR 0.39, 95% CI 0.32-0.49), or severe pain (OR 0.23, 95% CI 0.18-0.29).

201 or scale (VDS) ("none", "mild", "moderate", "severe" pain) or a 100-mm visual analog scale (VAS) anch

202 ular inflammation without prominent redness, severe pain, or hypopyon.

203 oncentrations with acute (% time in moderate-severe pain over POD0-2) and chronic (pain score > 3/10

204 or a child with sciatic nerve zoster who had severe pain over the lower back 6 days before appearance

205 n, 29% mild pain, 18% moderate pain, and 10% severe pain over the past 7 days.

206 eater impairment of HRQOL compared with less severe pain (P < 0.0001).

207 rer general function (HAQ; P < 0.0001), more severe pain (P = 0.002), greater fatigue (P = 0.0005), g

208 ks, fewer NCPB patients reported moderate or severe pain (pain intensity rating of > or =5/10) vs opi

209 or chemotherapy had failed and who reported severe pain (pain score > or = 4 [scale of 0-10]) over a

210 ain management, pain severity, time spent in severe pain, pain interference, and satisfaction.

211 nduced neuropathy is characterized by acute, severe pain, peripheral nerve degeneration, and autonomi

212 If severe pain persists, a course of corticosteroids may be

213 using doubly robust estimation and included severe pain, poor mental health, asthma or bronchitis, h

214 chronic immune response eventually leads to severe pain, pus discharge, irreversible tissue destruct

215 al record abstraction, 1789 (79.8%) reported severe pain (rated most recent pain crises as >=7 out of

216 ould be offered to patients with moderate-to-severe pain related to cancer or active cancer treatment

217 ar efficacy in reducing early, moderate, and severe pain-related responses, suggesting that TRPV1 may

218 ent of analgesic agents for the treatment of severe pain requires the identification of compounds tha

219 gross hematuria, allograft pancreatitis, and severe pain requiring overnight hospitalization.

220 ue scale, with higher scores indicating more severe pain), return emergency department visits, hospit

221 4%, moderate pain (scores 5-7) in 34.5%, and severe pain (scores 8-10) in 7.1% of patients.

222 ecently started using prescribed opioids for severe pain (strong opioids for <=2 months or weak opioi

223 pain and less likely to receive opioids for severe pain, suggesting a different threshold for treatm

224 ache," "hurt," and "discomfort," may reflect severe pain symptoms, disability, and more serious joint

225 Inherited erythromelalgia (IEM), a severe pain syndrome characterized by episodes of intens

226 Cluster headache, one of the most severe pain syndromes in human beings, is usually descri

227 Cluster headache, one of the most severe pain syndromes in humans, is usually described as

228 can suffer breakthrough pain (BTP), episodic severe pain that "breaks through" the medication.

229 These patients suffer from bouts of severe pain that are minimally relieved by pain medicati

230 otal hip arthroplasty can cause moderate and severe pain that can have a profound impact during posto

231 iring joint replacement and with moderate-to-severe pain that had been inadequately controlled by wea

232 fects to analgesic treatment for moderate to severe pain that interfered with functional activity; ho

233 ximately 5% to 10% of survivors have chronic severe pain that interferes with functioning.

234 to blunt thoracic trauma typically result in severe pain that is notoriously difficult to manage.

235 arge proportion of patients have moderate to severe pain that needs treatment with opioid analgesics.

236 fever is a debilitating disease that causes severe pain to the joints, which can compromise the pati

237 ity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semag

238 e) aged 4 to 65 years with acute moderate to severe pain typical of painful vaso-occlusive episodes r

239 In men, the risk of severe pain was 8.70% vs 4.88%, respectively (risk diffe

240 More severe pain was associated with greater impairment of HR

241 Chronic severe pain was experienced by 37% of MMTP patients (95%

242 Severe pain was inversely associated with a transition t

243 Severe pain was reported by 4 patients in the TEP group

244 Nurse detection of moderate to severe pain was significantly associated with opioid tre

245 patients with OA of the knee and moderate-to-severe pain were enrolled in a randomized, double-blind,

246 Patients with moderate or severe pain were less likely to die at home (OR, 0.56; 9

247 Those with severe pain were more likely than those with lower level

248 and procedures not typically associated with severe pain were most strongly associated with new persi

249 atients who required therapy for moderate to severe pain were randomized to CR oxycodone every 12 hou

250 0 to 100, with higher scores indicating more severe pain) were similar in the placebo, lavage, and de

251 DRG neuron hyperexcitability associated with severe pain, whereas loss of the Na(v)1.7 channel in pat

252 dney failure (HDKF) have chronic moderate-to-severe pain, which is similar to the burden of pain in p

253 nitially reported pain on most days and more severe pain while walking (P < 0.05).

254 arly in patients with moderate to moderately severe pain who do not respond to or who cannot tolerate

255 from 0 to 10 points); those with moderate to severe pain, who had at least one metastatic candidate t

256 represent a new approach to the treatment of severe pain with an improved safety profile.

257 ing severe unrelenting pain alone (group 1), severe pain with intermittent acute exacerbations (group

258 All subjects developed severe pain within 8 weeks of intensive glucose control.